Agent for increasing the activity of the secretory phospholipase A2-IIA

摘要

The invention relates to an increase in the expression and / or scretion of sPLA¶2¶-IIA by the inhibition of certain signaling pathways. DOLLAR A The expression of sPLA¶2¶-IIA (secretory phospholipase A¶2¶, group IIA) according to the invention by inhibitors of the Rho / Rho-kinase signaling pathway, the Ras / Raf / MEK / ERK signaling pathway and the Ras / PI3 Increased kinase / Akt signaling pathway. DOLLAR A These inhibitors are therefore suitable according to the invention for the treatment of diseases characterized by defective expression and / or secretion of sPLA¶¶¶ IIA, and for the treatment of bacterial or fungal infectious diseases to sepsis. DOLLAR A A combination of different inhibitors leads to a synergistic increase in sPLA¶2¶-IIA expression or secretion. In addition, lower inhibitor concentrations can be used in the combination than when used alone.